Copyright
©The Author(s) 2024.
World J Clin Cases. Jan 6, 2024; 12(1): 15-23
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.15
Published online Jan 6, 2024. doi: 10.12998/wjcc.v12.i1.15
Table 1 Baseline characteristics of patients in the two groups
| Group | Gender (male/female) | Age (yr) | Average age (yr) | Primary lesion site (n) | Metastasis site (n) | ||||
| Left-sided colorectal | Right-sided colon | Liver | Bone | Lung | Abdominal cavity | ||||
| Observation group (n = 47) | 23/24 | 60-83 | 72.25 ± 6.41 | 31 | 16 | 19 | 12 | 11 | 5 |
| Control group (n = 47) | 22/25 | 60-82 | 72.19 ± 6.37 | 30 | 17 | 18 | 13 | 10 | 6 |
- Citation: Zhou DB, Cheng J, Zhang XH. Evaluating combined bevacizumab and XELOX in advanced colorectal cancer: Serum markers carcinoembryonic antigen, carbohydrate antigen 125, carbohydrate antigen 199 analysis. World J Clin Cases 2024; 12(1): 15-23
- URL: https://www.wjgnet.com/2307-8960/full/v12/i1/15.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v12.i1.15